“…In addition to high-throughput sequencing of cffDNA fragments, circulating fetal cells containing intact genome information with high purity provide another promising target for noninvasive genetic diagnosis. − So far, different kinds of fetal cells, including trophoblast cells, hematopoietic progenitor cells, fetal lymphocytes, and fetal NRBCs, have been identified in maternal circulation. ,, Among them, fNRBCs have advantages such as fetal rather than placental origin and short lifetime during maternal circulation, making them an optimal target for cell-based NIPT. − With the advancement of single-cell genetic analysis, the development of reliable strategies for rare circulating fetal cell enrichment from maternal peripheral blood remains one of the biggest obstacles to the clinical translation of cfNRBC-based NIPT. In past decades, different fetal cell enrichment technologies have been developed based on their biochemical or biophysical properties, such as magnetic- or fluorescence-activated cell sorting, , microfluidics, − dielectrophoresis, and cell size-based isolation .…”